Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Sees Large Decrease in Short Interest

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a significant decline in short interest in the month of January. As of January 30th, there was short interest totaling 693,745 shares, a decline of 97.6% from the January 15th total of 29,166,975 shares. Based on an average trading volume of 1,796,547 shares, the days-to-cover ratio is presently 0.4 days. Currently, 34.8% of the shares of the company are short sold. Currently, 34.8% of the shares of the company are short sold. Based on an average trading volume of 1,796,547 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Trading of Aspire Biopharma

Several institutional investors and hedge funds have recently modified their holdings of the business. Crewe Advisors LLC increased its position in Aspire Biopharma by 100.0% during the second quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock worth $169,000 after buying an additional 313,427 shares in the last quarter. Optivise Advisory Services LLC lifted its position in shares of Aspire Biopharma by 120.9% in the second quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock valued at $63,000 after acquiring an additional 128,660 shares in the last quarter. Jane Street Group LLC increased its position in Aspire Biopharma by 625.8% during the 2nd quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after purchasing an additional 131,533 shares in the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new position in Aspire Biopharma in the 3rd quarter valued at about $28,000. Hedge funds and other institutional investors own 19.17% of the company’s stock.

Wall Street Analyst Weigh In

ASBP has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Aspire Biopharma to a “sell” rating in a research report on Saturday, January 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Aspire Biopharma Price Performance

NASDAQ ASBP opened at $1.35 on Thursday. Aspire Biopharma has a 1-year low of $1.21 and a 1-year high of $632.00. The company has a market capitalization of $3.63 million, a P/E ratio of -0.07 and a beta of 0.81. The business has a 50 day moving average price of $3.16 and a 200 day moving average price of $10.16.

Aspire Biopharma (NASDAQ:ASBP) last posted its earnings results on Friday, November 14th. The company reported ($1.60) EPS for the quarter. The business had revenue of $0.00 million during the quarter.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.